<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624273</url>
  </required_header>
  <id_info>
    <org_study_id>SDN-D-002G</org_study_id>
    <secondary_id>SDN-D-002G</secondary_id>
    <nct_id>NCT00624273</nct_id>
  </id_info>
  <brief_title>Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis</brief_title>
  <acronym>Sildenafil</acronym>
  <official_title>Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study analyzing the effect of sildenafil therapy on digital ulcers in&#xD;
      systemic sclerosis. We want to analyze ulcer healing by measuring the size of digital ulcers&#xD;
      and their count and analyze the effect of sildenafil on angiography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INVESTIGATOR: Dr. Gabriela Riemekasten Anke Praast Prof. G. R. Burmester Prof. Falk Hiepe&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Sildenafil is a very potent drug in the treatment of digital ulcers secondary to Raynaud´s&#xD;
      phenomenon in patients with connective tissue diseases. Probably, sildenafil has a&#xD;
      disease-modifying capability improving different signs of a disturbed regulation of vascular&#xD;
      tone in connective tissue diseases. Sildenafil can be used over a long period without&#xD;
      significant side effects in scleroderma patients and improves disease severity, life quality,&#xD;
      and prognosis of patients with connective tissue diseases and secondary Raynaud's phenomenon.&#xD;
&#xD;
      SUBJECTS and CENTERS:&#xD;
&#xD;
      We want to study 10-15 patients with digital ulcers secondary to connective tissue diseases&#xD;
      and which are refractory to other drugs, such as calcium channel blockers or iloprost. In&#xD;
      this pilot study, patients are treated only in the Charité University Hospital.&#xD;
&#xD;
      INCLUSION/EXCLUSION CRITERIA&#xD;
&#xD;
      1 . Digital gangrene, ulcers in patients with severe secondary Raynaud's phenomenon&#xD;
&#xD;
      2. Stable therapy with vasoactive drugs, such as calcium channel blockers, angiotensin&#xD;
      inhibitors/AT II receptor antagonists or pentoxifyllin 4 weeks before and during the&#xD;
      treatment with sildenafil.&#xD;
&#xD;
      3. Unchanged immunosuppressive therapy 3 months before treatment with sildenafil&#xD;
&#xD;
      4. No effect of prostacyclin treatment, contraindications for prostacyclins, or other reasons&#xD;
      excluding this therapy&#xD;
&#xD;
      EXCLUSION CRITERIA:&#xD;
&#xD;
        1. Therapy with iloprost during the last 4 weeks&#xD;
&#xD;
        2. Sympathectomy during the last 4 weeks&#xD;
&#xD;
        3. TIA, stroke, myocardial infarction during the last 6 months&#xD;
&#xD;
        4. Instable angina pectoris&#xD;
&#xD;
        5. Hemorrhagic diathesis, thrombocytic dysfunction, fibromuscular dysplasia&#xD;
&#xD;
        6. Microangiopathic hemolytic anaemia&#xD;
&#xD;
        7. Azotaemia&#xD;
&#xD;
        8. Hypertonus not adjustable with diuretic, clonidine, ACE inhibitors/AT II antagonists,&#xD;
           calcium channel blockers)&#xD;
&#xD;
        9. Left ventricular ejection fraction&lt; 20%&#xD;
&#xD;
       10. Hypotonus &lt; 80/40 mm Hg&#xD;
&#xD;
       11. Positive pregnancy test&#xD;
&#xD;
       12. History of cancer&#xD;
&#xD;
       13. History of gastric/duodenic ulcers without endoscopic proof of complete healing&#xD;
&#xD;
       14. Participation in other studies (currently or during the last 4 weeks)&#xD;
&#xD;
       15. Abuse of alcohol or other drugs, smoker&#xD;
&#xD;
       16. Cardiac failure, use of nitrates&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      This is an open prospective pilot study of one centre determining the effect of a 6 month&#xD;
      treatment of sildenafil in patients with acral ulcers in secondary Raynaud's phenomenon due&#xD;
      to connective tissue diseases.&#xD;
&#xD;
      Drop out criteria's/ final points:&#xD;
&#xD;
      1 . Any change of the immunomodulating or suppressing therapy (e.g., treatment with&#xD;
      cyclophosphamide because of an alveolitis; bolus of steroids &gt; 30 mg/d).&#xD;
&#xD;
      2. No response on the healing of ulcers after 4 weeks of treatment with sildenafil 3.&#xD;
      Manifestation of new ulcers/necrosis under sildenafil 4. Escalation of medication with an&#xD;
      vascular influence (calcium channel blockers, ACE inhibitors/AT II receptor blockers)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>healing of digital ulcer</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of frequency/duration of Raynaud's attacks (monthly)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of necroses manifestations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Active Digital Ulcers</condition>
  <arm_group>
    <arm_group_label>1, active ulcers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sildenafil treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil therapy</intervention_name>
    <description>oral use</description>
    <arm_group_label>1, active ulcers</arm_group_label>
    <other_name>start at 25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Digital gangrene, ulcers in patients with severe secondary Raynaud's phenomenon&#xD;
&#xD;
          2. Stable therapy with vasoactive drugs, such as calcium channel blockers, angiotensin&#xD;
             inhibitors/AT II receptor antagonists or pentoxifyllin 4 weeks before and during the&#xD;
             treatment with sildenafil.&#xD;
&#xD;
          3. Unchanged immunosuppressive therapy 3 months before treatment with sildenafil&#xD;
&#xD;
          4. No effect of prostacyclin treatment, contraindications for prostacyclins, or other&#xD;
             reasons excluding this therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Therapy with iloprost during the last 4 weeks&#xD;
&#xD;
          2. Sympathectomy during the last 4 weeks&#xD;
&#xD;
          3. TIA, stroke, myocardial infarction during the last 6 months&#xD;
&#xD;
          4. Instable angina pectoris&#xD;
&#xD;
          5. Hemorrhagic diathesis, thrombocytic dysfunction, fibromuscular dysplasia&#xD;
&#xD;
          6. Microangiopathic hemolytic anaemia&#xD;
&#xD;
          7. Azotaemia&#xD;
&#xD;
          8. Hypertonus not adjustable with diuretic, clonidine, ACE inhibitors/AT II antagonists,&#xD;
             calcium channel blockers)&#xD;
&#xD;
          9. Left ventricular ejection fraction&lt; 20%&#xD;
&#xD;
         10. Hypotonus &lt; 80/40 mm Hg&#xD;
&#xD;
         11. Positive pregnancy test&#xD;
&#xD;
         12. History of cancer&#xD;
&#xD;
         13. History of gastric/duodenic ulcers without endoscopic proof of complete healing&#xD;
&#xD;
         14. Participation in other studies (currently or during the last 4 weeks)&#xD;
&#xD;
         15. Abuse of alcohol or other drugs, smoker&#xD;
&#xD;
         16. Cardiac failure, use of nitrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Gabriela Riemekasten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitätsklinik Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riemekasten, PD Dr. med.</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2003</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Gabriela Riemekasten</name_title>
    <organization>Charité Universitäsmedizin</organization>
  </responsible_party>
  <keyword>digital ulcers,</keyword>
  <keyword>systemic sclerosis,</keyword>
  <keyword>sildenafil,</keyword>
  <keyword>vasoactive therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

